KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial.

Graham Roberts, Jocelyne Just, Hendrik Nolte, Ole Holm Hels, Andrzej Emeryk, Carmen Vidal

Allergy 80(12) 3401-3411

PMID41064908
PMCIDPMC12666737
DOI10.1111/all.70073
发表日期2025-10-09
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 forest plot;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:森林图/亚组分析图。
摘要

摘要

BACKGROUND: In children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT-11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5-17 years) with HDM allergic asthma. METHODS: This phase III, randomised, double-blind, placebo-controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long-acting beta-agonists, to daily treatment with SQ HDM SLIT-tablet or placebo for 24-30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial. RESULTS: The rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM-SLIT tablet; superiority over placebo was not established. Most treatment-related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma-related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT-tablet group. CONCLUSION: As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT-tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016-004363-39.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Primary and key secondary efficacy endpoint analysis (FAS, primary estimand). The key secondary endpoints could not be formally tested in the hierarchy and, therefore, p ‐values are not presented. † Measured using an eDiary over a 14‐day period, once every 4 months. ‡ Measured every 4 months. CI, confidence interval; FAS, full analysis set; FEV 1 , forced expiratory volume in 1 s; HDM, house dust mite; n obs , number of subjects with observations contributing to the analysis; SABA, short‐acting beta‐2‐agonist; SLIT, sublingual immunotherapy.
非 KM Figure
FIGURE 2FIGURE 2 Changes from baseline in immunological parameters—HDM‐specific IgE, IgG 4 , and IgE‐BF (FAS). Numbers within the panel represent the number of subjects contributing to the adjusted mean. CI, confidence interval; FAS, full analysis set; HDM, house dust mite; IgE, immunoglobulin type E; IgE‐BF, immunoglobulin type E‐blocking factor; IgG 4 , immunoglobulin type G 4 ; SLIT, sublingual immunotherapy.
非 KM Figure
FIGURE 3FIGURE 3 Asthma‐related events (safety analysis set). HDM, house dust mite; SLIT, sublingual immunotherapy.
非 KM Figure
FIGURE 4FIGURE 4 Post hoc analysis of asthma‐related events (regardless of causality) according to ACQ total score at baseline (safety analysis set). Panels A–E show all events reported irrespective of whether the investigator reported them as treatment‐related or not. The post hoc analysis of asthma‐related events according to asthma control at baseline assigned using ACQ total score thresholds from GINA: ACQ ≤ 0.75 = well controlled; ACQ > 0.75 to < 1.5 = neither well nor poorly controlled; ACQ ≥ 1.5 = poorly controlled. The overall number of subjects in each subgroup was: For placebo, ACQ ≤ 0.75 n = 94, ACQ > 0.75 to < 1.5 n = 77, ACQ ≥ 1.5 n = 89 (three subjects had missing ACQ data at baseline); for SQ HDM SLIT‐tablet, ACQ ≤ 0.75 n = 87, ACQ > 0.75 to < 1.5 n = 88, ACQ ≥ 1.5 n = 90 (five subjects had missing ACQ data at baseline). ACQ, Asthma Control Questionnaire; HDM, house dust mite; SLIT, sublingual immunotherapy.
非 KM Figure